Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-259.34M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -92.21% |
| Return on Assets (Trailing 12 Months) | -81.34% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.64 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.74 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 169.86M |
| Free Float | 159.84M |
| Market Capitalization | $2.53B |
| Average Volume (Last 20 Days) | 1.08M |
| Beta (Past 60 Months) | 0.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |